Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...
The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...
according to Novo Nordisk. Diabetes is a key risk factor for kidney disease. Roughly 40% of Type 2 diabetes patients have the condition, which can cause additional sickness such as increased risk ...
The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs such as semaglutide (Ozempic or Wegovy), has been censured by the UK’s Prescription Medicines Code of Practice ...
A new study found that patients taking GLP-1s to treat type 2 diabetes have a lower risk of developing Alzheimer’s disease, potentially opening the door … ...
which could influence Novo Nordisk's stock by approximately 5-10%, depending on the discussion around why only 57% of patients in the first study received the highest dose. The second factor is ...
Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...
Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. Credit: © 2025 Novo Nordisk A/S. Novo Nordisk’s high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback